Lonza Group Ag (OTCMKTS:LZAGY - Get Free Report) was the recipient of a significant decrease in short interest in March. As of March 13th, there was short interest totaling 3,903 shares, a decrease of 87.6% from the February 26th total of 31,431 shares. Based on an average daily volume of 149,464 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the stock are sold short. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 149,464 shares, the short-interest ratio is presently 0.0 days.
Wall Street Analysts Forecast Growth
LZAGY has been the topic of several analyst reports. Zacks Research cut Lonza Group from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 4th. Royal Bank Of Canada upgraded shares of Lonza Group from a "hold" rating to a "moderate buy" rating in a research report on Wednesday, February 11th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold".
View Our Latest Stock Report on LZAGY
Lonza Group Price Performance
Shares of OTCMKTS:LZAGY traded up $0.47 during trading on Tuesday, hitting $60.13. 122,381 shares of the company's stock were exchanged, compared to its average volume of 85,412. The company has a quick ratio of 1.77, a current ratio of 2.24 and a debt-to-equity ratio of 0.42. The firm has a 50-day moving average price of $66.74 and a two-hundred day moving average price of $67.56. Lonza Group has a 1-year low of $55.57 and a 1-year high of $73.85.
Lonza Group Company Profile
(
Get Free Report)
Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza's client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.
The company's core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lonza Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lonza Group wasn't on the list.
While Lonza Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.